
Company Introduction
Founded in May 2018, Belief BioMed (BBM) is an industry leader in gene therapy product development, production and clinical application. BBM is committed to the development of safe and efficient adeno-associated virus based gene therapies. AAV vector technology provides more effective innovative gene therapy for genetic diseases with gene defects, neurodegenerative diseases, age-related degenerative diseases and some major malignant diseases. Headquartered in Shanghai, the group also has offices and production centers in Beijing, Suzhou, Hong Kong and North Carolina.
The company has developed hundreds of key technologies of AAV vectors, and owns dozens of world-leading patent technologies, including the world-leading HEK293 cell suspension serum-free culture process and full-chromatography large-scale purification process, and established the first commercialized production platform of clinical-grade AAV gene therapy drugs in China. The company has carried out a comprehensive layout in the fields of new capsids targeting different tissues of AAV, efficient design of transgenic expression boxes, advanced clinical-grade vector manufacturing process, innovative clinical development paradigm and so on. At the same time, it has also established a rich R&D pipeline for the treatment of hemophilia, Parkinson's disease, lysosomal storage disease, hereditary neuromuscular diseases, ophthalmology and degenerative diseases of the elderly, and many other major and unmet clinical needs. Multiple product pipelines have entered various pre-clinical studies or IND applications and have collected clinical data showing good safety and efficacy.
Mission And Vision

Our Mission
Make gene therapy drugs available, affordable and healable.

Our Vision
To become the pioneer leading China’s gene therapy industry, to bring China’s gene therapy drugs to the world.
Key Milestones
Management Team

Xiao Xiao
Co-Founder, Chairman and CSO, Ph.D.
Ph.D. in Molecular Biology, University of Pittsburgh
Co-founder of Bamboo / Askbio

Jane Zheng
Co-founder and CEO, Ph.D.
PhD from Institute of Neurology, Chinese Academy of Sciences
Co-founder of Genechem / Neuron Biotech

Hao Zheng
Operations Senior VP
Tianjin university Pharmaceutical engineering, Bachelor
15 years of experience in pharmaceutical operation management

Hui Chen
Portfolio Regulatory, VP
Fudan University, Master
19 years of experience in pharmaceutical R&D

Xia Wu
Pipeline R&D, VP
Utah State University, Postdoc.
15 years of experience in AAV early discovery

Wei Jiang
Analytical Development, Senior Director
Institute of Biochemistry, CAS, Ph.D.
8 years of experience in AAV vector application

Zengmin Du
Process R&D, Senior Director
East China University of Science and Technology, Ph.D.
8 years of experience in AAV vector R&D

Philip Sin
SVP
Corporate Funding and Development Department
Dartmouth College , Economics Bachelor
Senior financial services executive with 20 years of experience

Yuntao Gong
Medical VP
Peking University, Neuroscience, Ph.D.
15 years of experience in Clinical Development/Medical Affairs

Yue Dun
Clinical Vice President
Peking University, Master
15 years of experience in clinical development